Ranitidine

CONTRAINDICATIONS:

- Hypersensitivity to ranitidine or any component of the formulation

WARNING:

- This product is not for intravenous use

PRECAUTIONS:

- In patients with renal impairment, the dose should be reduced to 300 mg qd

ADVERSE REACTIONS:

- The most common adverse reactions are headache, dizziness, diarrhea, and nausea.

DOSAGE AND ADMINISTRATION:

- Adults: Initial dose of 150 mg qd, may be increased to 300 mg qd if needed

PHARMACODYNAMICS:

- Ranitidine is a histamine H2 receptor antagonist that inhibits gastric acid secretion.

PHARMACOKINETICS:

- Ranitidine is rapidly absorbed after oral administration and is extensively metabolized in the liver.

INTERACTIONS:

- CYP2C19 inhibitors: Coadministration with strong CYP2C19 inhibitors may increase the risk of adverse effects

SERIAL RECOMMENDATIONS:

- Ranitidine is not recommended for long-term use due to potential for tolerance and rebound hypersecretion.

REFERENCES: